Until then, the most accurate answer is: Retatrutide is the higher-upside candidate, while CagriSema is the more incremental combination strategy
The Absence of Clinical Data The lack of formal research on cagrilintide dosage with retatrutide combinations stems from several factors: Competitive development Novo Nordisk (cagrilintide) and Eli Lilly (retatrutide) are pharmaceutical competitors with no incentive to study each other's compounds together Regulatory pathways Both medications remain in phase 3 development without FDA approval for metabolic applications Safety unknowns Drug-drug interactions, additive side effects, and optimal dosing ratios remain completely uncharacterized For wellness professionals and peptide researchers, this data gap presents significant challenges in developing evidence-based protocols
To see my deep-dive analysis from when this trend first escalated, you can watch my original video below: A Gastroenterologists Approach: Evidence Based Assessment If you have persistent gut symptoms, recurrent flares, bloating, food intolerance or concerns about inflammatory bowel disease, it is important not to rely on unproven supplements or online peptide claims alone
The short answer is that it depends
You can also watch episodes on YouTube at My profound breath-work session w/ Damian "Wim" Glynn [PART TWO] Part 1 was the theory, now we're putting it into practice
